$EWTX News

HC Wainwright & Co. Maintains Buy on Edgewise Therapeutics, Raises Price Target to $45

RBC Capital Maintains Outperform on Edgewise Therapeutics, Lowers Price Target to $48

Wedbush Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $52

Edgewise To Sell Its Muscular Dystrophy Business To Servier For $1.55B In Cash Up Front And Up To $1.1B In Further Milestone Payments For Aggregate Potential Sum Of Up To $2.65B

Edgewise Therapeutics (NASDAQ:EWTX) Beats Q1 Estimates as Long-Term Data Strengthens Case for Sevasemten

Edgewise Therapeutics Q1 EPS $(0.46) Beats $(0.50) Estimate

JP Morgan Maintains Overweight on Edgewise Therapeutics, Raises Price Target to $45

Wedbush Reiterates Outperform on Edgewise Therapeutics, Maintains $32 Price Target

The $3B Biotech With Two Shots On Goal

Edgewise Therapeutics Presents At 2026 MDA Clinical And Scientific Conference, Long-Term Data From MESA Open-Label Extension Study Of Sevasemten In Becker Muscular Dystrophy

Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Evercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $45

Assessing Edgewise Therapeutics (EWTX) Valuation After Strong Multi‑Year Returns And Recent Share Price Momentum

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs

Edgewise Therapeutics Q4 EPS $(0.47) Misses $(0.43) Estimate

Edgewise Therapeutics Teases Phase 3 Sevasemten Readout, HCM Data Update at Guggenheim Conference

Assessing Edgewise Therapeutics (EWTX) Valuation After Recent Share Price Momentum

Why Edgewise Therapeutics Stock Crushed the Market on Monday